The activation of a group of genes called NTRK fusions can lead to cell growth and survival. These fusions appear to be cancerous irrespective of cancer lineage. The inhibition of NTRK fusion activation using Larotrectinib should reduce or suppress tumour cell growth and subsequently lead to cancer cell death.
|Effective start/end date||1/04/02 → 27/06/25|
- Robert Wood Johnson Foundation: $105,000.00